The objective of this task order supports niaids goal to conduct a series of standardized phase 1 and phase 2 trials on next-generation vaccines to generate data to inform decisions on which…
Active Awarded Last action
- Contract number
- 75N91023F00008
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $173,281,267
Award facts
- Contract value 100% obligated
- $173,281,267.00 Current and potential, with all options
- Completion date 56% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | $0 | |
| Other Administrative Action | -$119,352,799 | |
| Terminate for Convenience | $0 | |
| Other Administrative Action | $15,048,720 | |
| Original award | $277,585,346 |
About this award
The National Institute of Allergy and Infectious Diseases issued a $173.3 million delivery order to Leidos Biomedical Research Inc. on June 1, 2023, for Phase 1 and Phase 2 clinical trials of next-generation COVID vaccines to inform advanced development decisions. The order is issued under the NIAID master indefinite delivery contract HHSN261201500003I and carries a ceiling value of $173.3 million with an ultimate completion date of May 31, 2029.
Place of performance is Frederick, MD. The work is priced on a cost-plus-fixed-fee basis.
Service Contract Inventory reporting shows actual government-invoiced labor across three fiscal years: FY2023 at $7.5 million (2.7 FTEs, 5,702 contractor hours), FY2024 at $4.3 million (13.2 FTEs, 27,490 contractor hours), and FY2025 at $8.6 million (21.2 FTEs, 44,084 contractor hours). Derived government-paid hourly rates declined from $1,312.72 per hour in FY2023 to $158.07 per hour in FY2024, recovering to $194.25 per hour in FY2025. In FY2025, four subcontractors performed 60 percent of total contractor hours.
Description
The objective of this task order supports niaids goal to conduct a series of standardized phase 1 and phase 2 trials on next-generation vaccines to generate data to inform decisions on which candidates to support for advanced development.
Quick answers
Who was awarded contract 75N91023F00008?
75N91023F00008 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on June 1, 2023.
How much is contract 75N91023F00008 worth?
The government has obligated $173,281,267 on 75N91023F00008.
Which agency awarded contract 75N91023F00008?
National Cancer Institute (National Institutes of Health) awarded 75N91023F00008, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91023F00008 an order under another contract?
Yes. 75N91023F00008 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91023F00008 competed?
The extent of competition for 75N91023F00008 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award